• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Neuronetics Inc.

    5/29/26 5:28:14 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care
    Get the next $STIM alert in real time by email
    SD 1 d141664dsd.htm SD SD
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM SD

     

     

    SPECIALIZED DISCLOSURE REPORT

     

     

    NEURONETICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-38546

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    file number)

    3222 Phoenixville Pike

    Malvern, PA

      19355
    (Address of principal executive offices)   (Zip Code)

    W. Andrew Macan

    (877) 600-7555

    (Name and telephone number, including area code, of the person to contact in connection with this report.)

     

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed:

     

    ☒

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2025.

     

    ☐

    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended December 31, 2025.

     

     
     


    Section 1 – Conflict Minerals Disclosure

    Item 1.01 Conflict Minerals Disclosure and Report

    In accordance with the disclosure requirements promulgated by the U.S. Securities and Exchange Commission, Neuronetics, Inc. (the “Company”) has undertaken efforts to determine its conflict minerals1 reporting requirements for the period from January 1 to December 31, 2025.

    The Company has filed this Specialized Disclosure Report and the associated Conflict Minerals Report, which appears as Exhibit 1.01 hereto and is publicly available through the Company’s website at ir.neuronetics.com/corporate-governance/highlights.

    Item 1.02 Exhibit

    The Company has filed as an Exhibit to this Form SD its Conflict Minerals Report for calendar year ended December 31, 2025.

     

    1 

    The term “conflict mineral” is defined in Section 1502(e)(4) of the Dodd-Frank Wall Street Reform and Consumer Protection Act as (A) columbite-tantalite, also known as coltan (the metal ore from which tantalum is extracted); cassiterite (the metal ore from which tin is extracted); gold; wolframite (the metal ore from which tungsten is extracted); or their derivatives; or (B) any other mineral or its derivatives determined by the Secretary of State to be financing conflict in the Democratic Republic of the Congo or an adjoining country.


    Section 2 – Resource Extraction Issuer Disclosure

    Item 2.01 Resource Extraction Issuer Disclosure and Report

    Not applicable.

    Section 3 – Exhibits

    Item 3.01 Exhibits

    The following exhibit is filed as part of this report.

    Exhibit 1.01 – Neuronetics, Inc.’s Conflict Minerals Report for the reporting period from January 1 to December 31, 2025.

    *****


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

    Neuronetics, Inc.
    By:  

    /s/ W. Andrew Macan

      W. Andrew Macan
      Executive Vice President, Chief Legal Officer, and Corporate Secretary

    Date: May 29, 2026

    Get the next $STIM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STIM

    DatePrice TargetRatingAnalyst
    8/13/2024Outperform → Mkt Perform
    William Blair
    10/14/2021$18.00 → $12.00Market Outperform
    JMP Securities
    10/13/2021Outperform → Mkt Perform
    William Blair
    10/13/2021Buy → Neutral
    BTIG
    More analyst ratings

    $STIM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neuronetics Appoints Robert Greene as Senior Vice President Sales

    MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced that Robert Greene has been appointed as the company's Senior Vice President Sales, effective June 1, 2026. Rob brings extensive experience leading commercial strategy and sales organizations within healthcare and medical technology, including capital equipment and service. Inducement Grant under Nasdaq Listing Rule 5635(c)(4) In connection with his hiring on June 1, 2026, the Co

    6/2/26 4:30:00 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

    MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced a strategic partnership with ANT Neuro, a global leader in precision brain mapping and neuronavigation technologies, to expand the capabilities of the NeuroStar® Advanced Therapy System with advanced image-guided navigation technology.  Through this preferred partnership, Neuronetics will offer ANT Neuro's visor2™ neuronavigation system alongside NeuroStar TMS, enabling healthcare p

    5/14/26 8:32:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics Reports First Quarter 2026 Financial and Operating Results

    MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics"), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2026. First Quarter 2026 Highlights First quarter 2026 revenue of $34.5 million, up 8% compared to the first quarter 2025U.S. clinic revenue of $21.5 million, up 15% compared to the first quarter 2025Shipped 34 NeuroStar systems in the US; a 10% increase compared to

    5/5/26 7:50:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Chernett Jorey bought $117,000 worth of shares (100,000 units at $1.17), increasing direct ownership by 0.96% to 10,553,988 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    5/20/26 12:39:34 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Large owner Chernett Jorey bought $636,500 worth of shares (475,000 units at $1.34), increasing direct ownership by 5% to 10,453,988 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    5/13/26 8:31:28 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Director Cascella Robert bought $75,000 worth of shares (100,000 units at $0.75), increasing direct ownership by 28% to 453,098 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    9/13/24 5:02:03 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rosengarten Megan was granted 30,000 shares, increasing direct ownership by 21% to 170,890 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    5/29/26 5:10:46 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Director Muir Glenn P was granted 30,000 shares, increasing direct ownership by 8% to 401,816 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    5/29/26 5:05:26 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Director Cucuz Sasha was granted 30,000 shares, increasing direct ownership by 2% to 1,542,798 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    5/29/26 5:04:01 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Neuronetics downgraded by William Blair

    William Blair downgraded Neuronetics from Outperform to Mkt Perform

    8/13/24 10:26:16 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    JMP Securities reiterated coverage on Neuronetics with a new price target

    JMP Securities reiterated coverage of Neuronetics with a rating of Market Outperform and set a new price target of $12.00 from $18.00 previously

    10/14/21 8:41:45 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics downgraded by William Blair

    William Blair downgraded Neuronetics from Outperform to Mkt Perform

    10/13/21 12:25:53 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    SEC Filings

    View All

    SEC Form SD filed by Neuronetics Inc.

    SD - Neuronetics, Inc. (0001227636) (Filer)

    5/29/26 5:28:14 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by Neuronetics Inc.

    8-K - Neuronetics, Inc. (0001227636) (Filer)

    5/29/26 4:45:06 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by Neuronetics Inc.

    8-K - Neuronetics, Inc. (0001227636) (Filer)

    5/22/26 7:30:06 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Leadership Updates

    Live Leadership Updates

    View All

    Neuronetics Appoints Robert Greene as Senior Vice President Sales

    MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced that Robert Greene has been appointed as the company's Senior Vice President Sales, effective June 1, 2026. Rob brings extensive experience leading commercial strategy and sales organizations within healthcare and medical technology, including capital equipment and service. Inducement Grant under Nasdaq Listing Rule 5635(c)(4) In connection with his hiring on June 1, 2026, the Co

    6/2/26 4:30:00 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer

    MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced the appointment of Dan Reuvers as the Company's next President and Chief Executive Officer, effective March 23, 2026. Mr. Reuvers will also join the Board of Directors at that time. He succeeds Keith Sullivan, who will step down as the Company's President and Chief Executive Officer on March 23, 2026 and retire on March 31, 2026 after five and a half years of leadin

    3/17/26 7:45:00 AM ET
    $IART
    $STIM
    $TCMD
    Medical/Dental Instruments
    Health Care

    Diality Appoints Peter Donato as Chief Financial Officer

    Life sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224064413/en/Diality CFO Peter Donato. Donato joins Diality with nearly 35 years of financial leadershi

    2/24/26 7:05:00 AM ET
    $MYGN
    $STIM
    $TFX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology

    $STIM
    Financials

    Live finance-specific insights

    View All

    Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced that it plans to release first quarter 2026 financial and operating results prior to market open on Tuesday, May 5, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/3pztkve5. To listen to the conf

    4/21/26 8:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics"), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it plans to release fourth quarter 2025 financial and operating results prior to market open on Tuesday, March 17, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-serv

    3/3/26 8:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

    All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth on an adjusted pro forma basisFull year 2025 revenue of $149.2 million, representing 99% year-over-year growth on an as reported basis and 15% year-over-year growth on an adjusted pro forma basisAchieved positive operating cash flow of $0.9 million in the fourth quarter 2025Ended 2025 with total cash of $34.1 million, inclusive of cash, cash equivalents and restricted cash MALVERN, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a verti

    2/10/26 4:34:49 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Neuronetics Inc.

    SC 13D - Neuronetics, Inc. (0001227636) (Subject)

    12/17/24 9:15:11 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

    SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

    11/14/24 1:42:23 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

    SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

    11/14/24 11:17:47 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care